Monoclonal antibodies (MAbs) against tumor-associated antigens, the preparation and use thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 9, 2005
Grant Date -
Jun 6, 2002
app pub date -
Dec 13, 1994
filing date -
Mar 24, 1989
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention relates to murine monoclonal antibodies (MAbs), A, B, C and D, which are directed against tumor-associated antigens. The nearly complete nucleotide sequences of the V genes of these MAbs are described, so that the relevant variable domains can be put together to give chimeric MAbs, or 'humanized' MAbs are obtained by inserting the hypervariable regions (complementarity determining regions=CDR) into a human MAb framework. Antibody constructs of this type can be employed in human therapy and in vivo diagnosis without the disadvantages observed with murine MAbs.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully